Last updated: February 22, 2026
What Is NDC 70000-0020 and Its Therapeutic Use?
NDC 70000-0020 identifies a specific drug formulation. According to available data, it corresponds to a carfilzomib formulation used in multiple myeloma treatment. Carfilzomib is a proteasome inhibitor with an approved indication for relapsed or refractory multiple myeloma (FDA, 2019).
Market Size and Demand Drivers
Patient Population
The annual global incidence of multiple myeloma exceeds 160,000 cases, with prevalence showing steady growth due to aging populations and improved diagnosis. The U.S. accounts for approximately 35,000 new cases annually (SEER, 2021).
Treatment Landscape
Carfilzomib competes mainly with bortezomib and ixazomib. Monotherapy and combination regimens see increasing use, establishing steady demand. Market adoption is driven by:
- Expanded indications for newly diagnosed and relapsed cases
- Favorable safety profile relative to competitors
- Rising approval of combination regimens involving carfilzomib (e.g., with dexamethasone, elotuzumab)
Market Trends
The multiple myeloma drug market generated approximately $10 billion in revenue in 2021, projected to grow at a compound annual growth rate (CAGR) of 8.2% through 2027 (IQVIA, 2022). Carfilzomib's share within the proteasome inhibitor segment is estimated at 35%.
Competitive Landscape
| Drug Name |
Market Share |
Estimated 2022 Revenue |
Key Competitors |
FDA Approval Year |
| Carfilzomib |
35% |
$3.5 billion |
Bortezomib, Ixazomib |
2012 |
| Bortezomib |
50% |
$5 billion |
Carfilzomib, Ixazomib |
2003 |
| Ixazomib |
15% |
$1.5 billion |
Bortezomib, Carfilzomib |
2015 |
Price Dynamics and Projections
Current Pricing
- Average wholesale price (AWP) per 60 mg vial: approximately $4,750 (Watson, 2022).
- Per treatment course (assuming 20 doses): roughly $95,000.
- Reimbursement landscape favors negotiated discounts, with net prices around 65-75% of AWP.
Historical Price Trends
From 2018 to 2022, the price per vial increased annually by approximately 3%. Price inflation reflects manufacturing costs, demand growth, and market exclusivity.
Future Price Projections (2023–2027)
Assuming moderate patent protection and high demand, wholesale prices are projected to grow at 2–3% annually. Increased competition or biosimilar entry could pressure prices downward, but current data suggests limited biosimilar presence for carfilzomib as of 2023.
| Year |
Projected AWP per 60 mg vial |
Notes |
| 2023 |
$4,880 |
2.7% growth |
| 2024 |
$5,005 |
2.6% growth |
| 2025 |
$5,135 |
2.5% growth |
| 2026 |
$5,275 |
2.7% growth |
| 2027 |
$5,420 |
2.6% growth |
Market Penetration and Pricing Strategies
Pharmaceutical companies are likely to adopt value-based pricing, especially as new combination therapies demonstrate improved efficacy and safety profiles.
Regulatory and Patent Considerations
- Patent expiring within 8–10 years, though some formulations may be protected by secondary patents.
- Potential biosimilar development could impact pricing and market share after 2028.
Summary
The market for NDC 70000-0020 is characterized by stable demand driven by multiple myeloma treatment needs. Current wholesale prices are approximately $4,750 per vial, with projections indicating modest annual increases. Market entry of biosimilars could alter pricing dynamics significantly beyond 2027.
Key Takeaways
- The drug serves an expanding multiple myeloma market with sustained demand.
- Estimated 2022 revenue for the product is around $3.5 billion.
- Prices are forecasted to grow modestly at 2–3% annually through 2027.
- Competitive pressures from biosimilars may lower prices after patent expiration.
- Adoption of combination regimens is a key growth driver, potentially impacting demand and pricing.
FAQs
1. How does the price of NDC 70000-0020 compare to similar drugs?
It is generally priced higher than older proteasome inhibitors, primarily due to its targeted mechanism and clinical efficacy, but remains competitive within its segment.
2. What factors could influence market demand for this drug?
Efficacy of combination therapies, approval of new indications, and evolving treatment guidelines significantly affect demand.
3. Are biosimilars expected to impact the price significantly?
Yes, biosimilar development could reduce prices by 20-30% post-patent expiry, impacting market share.
4. How do reimbursement policies affect pricing?
Negotiated discounts and payer policies determine net prices, often reducing list prices by 25–35%.
5. What is the likelihood of price stabilization or reduction?
Prices are likely to stabilize until biosimilar competition emerges; future reductions depend on regulatory and market developments.
References
- U.S. Food and Drug Administration (2019). FDA approves Kyprolis for relapsed multiple myeloma.
- SEER Program (2021). Cancer statistics review.
- IQVIA (2022). The Global Oncology Market Report.
- Watson, L. (2022). Pharmaceutical wholesale price reports.
